title: Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial.
abstract: An accelerated loss of lung function is one of the defining characteristics of chronic obstructive pulmonary disease (COPD). To date, the only successful intervention shown to conclusively attenuate the loss of lung function over time is smoking cessation. Pharmacological interventions including inhaled corticosteroids and ipratropium bromide have not altered the rate of decline of lung function. Tiotropium is an inhaled anticholinergic that provides 24-hour bronchodilation with once-daily dosing due to prolonged muscarinic M3 receptor blockade. Controlled clinical trials have suggested sustained efficacy for periods of up to one year. We therefore initiated a four-year, controlled clinical trial (UPLIFT, Understanding the Potential Long-Term Impacts on Function with Tiotropium) in patients with COPD to evaluate the long-term effects of tiotropium on the rate of decline in lung function and health status as well as the frequency of exacerbations. The design of such large, long-term clinical trials presents unique methodological challenges including the definition of endpoints, the quality and variability of spirometric measurements and premature patient discontinuations from the trial. The present manuscript outlines the rationale for the UPLIFT study, and reviews the study design and the steps taken to address methodological challenges experienced in other long term studies. Careful design and implementation of the UPLIFT trial is anticipated to yield high quality results that will help in increasing our understanding of the long term natural history of COPD in a global population as well as to elucidate the role that tiotropium can play in affecting the course of this debilitating disease.
authors.affiliation: Respiratory Division, University Hospitals, Leuven, Belgium. marc.decramer@uz.kuleuven.ac.be
authors.forename: Marc
authors.initials: M
authors.lastname: Decramer
authors.forename: Bartolome
authors.initials: B
authors.lastname: Celli
authors.forename: Donald P
authors.initials: DP
authors.lastname: Tashkin
authors.forename: Romain A
authors.initials: RA
authors.lastname: Pauwels
authors.forename: Deborah
authors.initials: D
authors.lastname: Burkhart
authors.forename: Cara
authors.initials: C
authors.lastname: Cassino
authors.forename: Steven
authors.initials: S
authors.lastname: Kesten
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D005500:Follow-Up Studies; D005541:Forced Expiratory Volume / Q000187:drug effects / Q000502:physiology*; D006304:Health Status; D006801:Humans; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000503:physiopathology*; D012602:Scopolamine Derivatives / Q000008:administration & dosage / Q000627:therapeutic use*; D013147:Spirometry; D013997:Time Factors; D000069447:Tiotropium Bromide; D016896:Treatment Outcome
chemical_list: D001993:Bronchodilator Agents; D012602:Scopolamine Derivatives; D000069447:Tiotropium Bromide